Pa. Court Remands State's Action Against Pharmaceutical Companies

PHILADELPHIA -- A federal court has remanded an action filed by the Commonwealth of Pennsylvania, ruling that a federal question does not exist in the assertion that the defendants' fraudulent drug promotion resulted in the submission of false claims to health care programs. Commonwealth of Pennsylvania v. Eli Lilly & Co., Inc., et al., No. 07-1083 (E.D. Pa.).

In a June 26 order, the U.S. District Court for the Eastern District of Pennsylvania found that while the causes of action asserted in the complaint involve a federal standard, they do not require a look at a disputed issue of federal …